Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies-Reference-Cited by-同舟云学术

Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies

Published:2016-11-02 Issue:4 Volume:31 Page:679-685
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Gottlieb A.B.¹,Lacour J.-P.²,Korman N.³,Wilhelm S.⁴,Dutronc Y.⁵,Schacht A.⁴,Erickson J.⁶,Zhang L.⁶,Mallbris L.⁶,Gerdes S.⁷

Affiliation:

1. Department of Dermatology; New York Medical College; Valhalla NY USA

2. Department of Dermatology; University Hospital of Nice; Nice France

3. Murdough Family Center for Psoriasis; University Hospitals Case Medical Center; Cleveland OH USA

4. Global Medical Affairs; Lilly Deutschland GmbH; Bad Homburg Germany

5. Regional Medical Affairs; Lilly France Neuilly-sur-Seine France

6. Eli Lilly and Company; Lilly Corporate Center; Indianapolis IN USA

7. Department of Dermatology; Psoriasis-Center; University Medical Center Schleswig-Holstein; Kiel Germany

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.13990/fullpdf

Reference17 articles.

1. The status of biologic therapies in the treatment of moderate to severe psoriasis;Menter;Cutis,2009

2. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions;Menter;J Am Acad Dermatol,2011

3. German S3-guidelines on the treatment of psoriasis vulgaris (short version);Nast;Arch Dermatol Res,2012

4. European S3-guidelines on the systemic treatment of psoriasis vulgaris;Pathirana;J Eur Acad Dermatol Venereol,2009

5. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009;Smith;Br J Dermatol,2009

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis;JAMA Dermatology;2024-08-01

2. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry;Drugs - Real World Outcomes;2024-06-24

3. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities;Expert Review of Clinical Pharmacology;2024-04-02

4. Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study;Acta Dermato-Venereologica;2023-11-21

5. Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients;JEADV Clinical Practice;2023-10-09